TCR² Therapeutics Inc.

Astellas Pharma, Inc. will book an impairment loss totalling JPY58.3bn ($437m) in the fourth quarter of its fiscal year just ended on 31 March, in a decision set to dent its previously forecast profi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Adaptimmune, TCR² Combine Forces, Incre

Raising venture capital or launching an initial public offering in 2023 is nowhere near as easy as it was in the record-breaking VC funding and IPO days of 2020 and 2021, after a rough 2022 when fundr

Despite the announcement of three significant M&A deals on the first day of this year’s J.P. Morgan Healthcare Conference, the boost to health care stocks that often accompanies the meeting has not ye